natgillin/translations-raw huggingface dataset:
These include the ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.).
Med njimi so ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti), CIBIC-Plus (Clinician’s Interview Based Impression of Change- Plus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).
These include the ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.).
Med njimi so ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo za kognicijo, ki temelji na storilnosti), CIBIC-Plus (Clinician’s Interview Based Impression of Change-Plus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).
These include the ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance-based measure of cognition) and the ADCS-CGIC (Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression of Change, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the ADCS-ADL (Alzheimer’s Disease Cooperative Study – Activities of Daily Living, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities related to finances).
Med njimi so ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti), ADCS-CGIC (Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression of Change, Zdravnikova ocena spremembe bolezni po Kooperativni študiji Alzheimerjeve bolezni, vsestranska globalna ocena bolnika, ki jo poda zdravnik ob upoštevanju negovalčeve ocene) in ADCS-ADL (Alzheimer’s Disease Cooperative Study – Activities of Daily Living, ocena vsakodnevnih aktivnosti po Kooperativni študiji Alzheimerjeve bolezni, negovalčeva ocena vsakodnevnih aktivnosti, med drugim osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanja zmožnosti orientacije v okolju kot tudi ukvarjanja z denarnimi zadevami).
These include the following:
Med njimi so naslednji:
These include, trouble sleeping, headache, nausea, feeling anxious, diarrhoea, flu- like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness.
Med temi so: težave s spanjem, glavobol, slabost s siljenjem na bruhanje, tesnoba, driska, gripi podobni simptomi, krči, živčnost, depresija, bolečina, potenje in omotica.
These include, trouble sleeping, headache, nausea, feeling anxious, diarrhoea, flu-like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness.
Med temi so: težave s spanjem, glavobol, slabost s siljenjem na bruhanje, driska, tesnoba, gripi podobni simptomi, krči, živčnost, depresija, bolečina, potenje in omotica.
These include:
Imunizacija
These include:
Med ta zdravila sodijo:
These include:
Med takšne spadajo:
These include:
Obsegajo:
These include:
Slednji vključujejo:
These include:
Taka zdravila so:
These include:
Takšna zdravila so:
These include:
Te spremembe so:
These include:
Ti so:
These include:
To so: antibiotik klaritromicin;
These include: antacid medicines to treat indigestion, heartburn or stomach ulcers (see also ‘When to take it’ in section 3)
Takšna zdravila so: antacidi, ki jih uporabljamo za zdravljenje prebavnih težav, zgage ali želodčne razjede (glejte tudi poglavje 3 »Kdaj vzeti zdravilo Revolade«).
These include: medicines for HIV infection (such as ritonavir, nelfinavir, amprenavir or fosamprenavir)
Med njimi so: zdravila za okužbo s HIV (na primer ritonavir, nelfinavir, amprenavir ali fosamprenavir),
These include: migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.
Ti vključujejo: migreno, otekanje obraza, resno alergijsko reakcijo, ki povzroči otekanje obraza in grla, resne kožne izpuščaje, nekatere motnje, ki vplivajo na pretok krvi v oči, nepravilno bitje srca, angino pektoris in nenadno srčno smrt.
These include: migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.
Ti vključujejo: migreno, otekanje obraza, resno alergično reakcijo, ki povzroči otekanje obraza in grla, resne kožne izpuščaje, nekatere motnje, ki vplivajo na pretok krvi v oči, nepravilno bitje srca, angino pektoris in nenadno srčno smrt.
These include: tenofovir containing medicines, used to treat HIV-1 infection and/or chronic hepatitis B infection
Ta vključujejo: zdravila, ki vsebujejo tenofovir, ki se uporabljajo za zdravljenje okužb z virusom HIV-1 in/ali okužb kroničnega hepatitisa B
These include: tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap), human papillomavirus (HPV), yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, rabies, hepatitis A and B vaccines.
Ta cepiva vključujejo: cepivo proti tetanusu, cepivo s prečiščenim toksoidom davice, acelularno cepivo proti oslovskemu kašlju (Tdap), cepivo proti okužbi s humanimi virusi papiloma (HPV), cepivo proti rumeni mrzlici, cepivo proti tifusni vročici (polisaharid Vi), cepivo proti japonskem encefalitisu, cepivo proti steklini, cepivo proti hepatitisu A in cepivo proti hepatitisu B.
These included bacterial, viral, or fungal infections.
Med temi okužbami so bile bakterijske, virusne in glivične okužbe.
These included cases of anaphylactic reactions/shock and angioedema, (see section 4.8).
To vključuje primere anafilaktičnih reakcij/šoka in angioedema (glejte poglavje 4.8).
These included definite or probable stent thrombosis at study end (0.9% vs 1.8%; HR 0.498; CI 0.364, 0.683); CV death, nonfatal MI, or urgent target vessel revascularisation through 30 days (5.9% vs 7.4%; HR 0.784; CI 0.688,0.894); all cause death, nonfatal MI, or nonfatal stroke through study end (10.2% vs 12.1%; HR 0.831; CI 0.751, 0.919); CV death, nonfatal MI, nonfatal stroke or rehospitalisation for cardiac ischaemic event through study end (11.7% vs 13.8%; HR 0.838; CI 0.762, 0.921).
Te so vključevale določene ali možne tromboze žilne opornice ob koncu študije (0,9 % proti 1,8 %; RT 0,498; IZ 0,364; 0,683); CV smrt, ne-smrtni MI ali urgentno ciljno žilno revaskulizacijo v 30 dneh (5,9 % proti 7,4 %; RT 0,784; IZ 0,688; 0,894); vse vzroke smrti, ne-smrtni MI ali ne-smrtno možgansko kap do konca študije (10,2 % proti 12,1 %; RT 0,831; IZ 0,751; 0,919); CV smrt, ne-smrtni MI, ne-smrtno možgansko kap ali ponovno hospitalizacijo zaradi srčnega ishemičnega dogodka do konca študije (11,7 % proti 13,8 %; RT 0,838; IZ 0,762; 0,921).
These included hypoglycaemia (frequency very common with the combination of sulphonylurea and metformin), influenza (common with insulin (with or without metformin)), nausea and vomiting (common with metformin), flatulence (common with metformin or pioglitazone), constipation (common with the combination of sulphonylurea and metformin), peripheral oedema (common with pioglitazone or the combination of pioglitazone and metformin), somnolence and diarrhoea (uncommon with metformin), and dry mouth (uncommon with insulin (with or without metformin)).
Ti so vključevali hipoglikemijo (pogostnost – zelo pogosta v kombinaciji s sulfonilsečnino in metforminom), gripo (pogostnost – pogosta z insulinom (z ali brez metformina)), navzeo in bruhanje (pogostnost – pogosta z metforminom), flatulenco (pogostnost – pogosta z metforminom ali pioglitazonom), zaprtje (pogostnost – pogosta v kombinaciji s sulfonilsečnino in metforminom), periferni edem (pogostnost – pogosta s pioglitazonom ali v kombinaciji s pioglitazonom in metforminom), zaspanost in diarejo (pogostnost – občasna z metforminom) in suha usta (pogostnost – občasna z insulinom (z ali brez metformina)).
These included major haemorrhages, reported at most in 4.2 % of the patients (surgical patients1).
To vključuje hude krvavitve, opisane pri ne več kot 4,2 % bolnikov (kirurški bolniki1).
These included salivation (rat and dog), pupil dilatation (dog), and two incidences of convulsions in dogs in the general toxicity study programme..
Med njimi so bili slinjenje (podgane in psi), dilatacija zenice (psi) in dve incidenci konvulzije pri psih v programu študije splošne toksičnosti.
These included three studies of echocardiography and three studies of Doppler.
V treh študijah so proučevali njegovo delovanje pri ehokardiografiji, v drugih treh pa pri Dopplerjevi sonografiji.
These included: dose-dependent adrenocortical toxicity in rats after 104 weeks of oral administration at approximately 3 to 10 times the mean steady-state AUC at the maximum recommended human dose and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at approximately 10 times the mean steady-state AUC at the maximum recommended human dose.
Med njimi so bili: adrenokortikalni toksični učinki pri podganah, odvisni od odmerka, po 104 tednih oralnega odmerjanja od 3- do 10-kratne srednje AUC ob največjem priporočenem odmerku za človeka ter povečana pogostnost adrenokortikalnih karcinomov in kombiniranih adrenokortikalnih adenomov/karcinomov pri podganjih samicah ob odmerjanju približno 10-kratno srednjo AUC v stanju dinamičnega ravnovesja ob največjem priporočenem odmerku za človeka.
These increases of plasma concentrations of co-administered medicinal products could increase or prolong their therapeutic effect and adverse events (see sections 4.3 and 4.5).
Zvečana koncentracija sočasno uporabljenih zdravil v plazmi lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke (glejte poglavji 4.3 in 4.5).
These increases were reversible in the majority of cases.
Ta povečanja so bila v večini primerov reverzibilna.
These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.
Te okužbe so pogosto povezane z velikim celotnim imunosupresivnim bremenom in lahko povzročijo resne ali smrtne bolezni, ki jih morajo zdravniki upoštevati pri diferencialni diagnozi pri imunosuprimiranih bolnikih s slabšajočo se ledvično funkcijo ali nevrološkimi simptomi.
These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.
Te okužbe so pogosto povezane z visokim skupnim imunosupresivnim bremenom in lahko vodijo do resnih ali usodnih stanj, kar morajo zdravniki upoštevati pri diferencialni diagnostiki pri bolnikih z oslabljenim imunskim odzivom v primeru pojava znakov slabšega delovanja ledvic ali nevroloških simptomov.
These infections have not consistently been recognised in patient taking TNF- antagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.
Takšne okužbe se pri uporabnikih antagonistov TNF niso pojavljale vedno, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
These infections have not consistently been recognised in patients taking TNF- antagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.
Takšne okužbe se pri uporabnikih antagonistov TNF niso pojavljale vedno, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
These infections have not consistently been recognised in patients taking TNF- antagonists and this resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.
Takšne okužbe se pri uporabnikih antagonistov TNF niso pojavljale vedno, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
These infections may be more serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other opportunistic infections and sepsis that may, in rare case, be life-threatening.
Te okužbe so lahko resne in vključujejo tuberkulozo, okužbe, ki jih povzročijo virusi, glive, paraziti ali bakterije ali druge oportunistične okužbe in sepso, in so lahko v redkih primerih smrtno nevarne.
These infections may be serious and include tuberculosis, infections caused by viruses, fungi or bacteria, or other opportunistic infections and sepsis that may be life-threatening.
Te okužbe so lahko resne in lahko vključujejo tuberkulozo ter virusne, glivične ali bakterijske okužbe ali druge oportunistične okužbe in sepso, kar je lahko življenjsko nevarno.
These infections may be serious and include tuberculosis, infections caused by viruses, fungi or bacteria, or other opportunistic infections and sepsis that may, in rare cases, be life-threatening.
Te okužbe so lahko resne in lahko vključujejo tuberkulozo ter virusne, glivične ali bakterijske okužbe ali druge oportunistične okužbe in sepso, ki je v redkih primerih lahko smrtno nevarna.
These infections may lead to septic shock, respiratory failure, renal failure, and/or multi- organ failure.
Te okužbe lahko povzročijo septični šok, odpoved dihal, odpoved ledvic in/ali odpoved več organov.
These infusion reactions were transient (resolved within 1 hour post-dosing) and were attributed to histamine release.
Te z infundiranjem povezane reakcije so bile prehodne (izzvenele so v eni uri po odmerku) in pripisane sproščanju histamina.
These ingredients may cause allergic reactions (possibly delayed).
Te sestavine lahko povzročijo alergijske reakcije (tudi zapoznele).
These injections may be justified even if it is not certain that you have hypoglycaemia.
Te injekcije utegnejo biti upravičene, tudi če niste prepričani, ali imate hipoglikemijo.
These instructions also tell you how to prepare the Betaferon solution for injection.
To navodilo opisuje tudi pripravo raztopine zdravila Betaferon za injiciranje.
These instructions are for taking a dose between 2 mg and 10 mg.
Naslednja navodila so primerna samo za jemanje odmerkov med 2 mg in 10 mg.
These instructions are for:
Ta navodila so za:
These instructions are written in this leaflet.
Navodila so napisana v tem Navodilu za uporabo.
These instructions do not take the place of talking with your healthcare professional about your medical condition or your treatment.
Ta navodila ne nadomeščajo odgovorov vašega zdravstvenega delavca glede vašega zdravstvenega stanja ali vašega zdravljenja.
These instructions show you how to prepare and give a dose of Isentress.
Ta navodila prikazujejo pripravo in dajanje zdravila Isentress.
These interactions are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of therapeutic effect.
Opisane interakcije temeljijo bodisi na študijah interakcij zdravila ali na interakcijah, napovedanih na podlagi pričakovanega obsega interakcij in možnih resnih neželenih učinkov ali izgube terapevtskega učinka.
These interactions are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.
Opisane interakcije temeljijo na študijah interakcij zdravila ali na interakcijah, napovedanih na podlagi pričakovanega obsega interakcij in možnih resnih neželenih učinkov ali izgube učinkovitosti.
These laboratory findings were generally observed within the first 12 weeks of treatment, were generally asymptomatic, and were reversible with dose interruption.
Ti laboratorijski izsledki, ki so jih običajno opazili v prvih 12 tednih zdravljenja, so bili večinoma asimptomatski in reverzibilni po prekinitvi odmerjanja.
These lead to 2- to 8-fold increases in bedaquiline MICs, resulting in bedaquiline MICs ranging from 0.25 to 0.50 mg/l.
Te vodijo v 2 do 8-kratno zvečanje MIK bedakilina, s koncentracijami od 0,25 do 0,50 mg/l.
These lesions are mild and resolve without treatment.The incidence of oral/skin lesions increases with increasing dose.
Incidenca poškodb v ustih in na koži narašča z večanjem odmerka.
These lesions are usually removed by surgery and people can continue treatment.
Te kožne spremembe se običajno odstrani s kirurškim posegom, bolnik pa lahko nadaljuje z zdravljenjem.
These lesions were not observed in macaques; decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan.
znižanje kalija v serumu med uporabo hidroklorotiazida, ki je bilo med kombiniranim dajanjemz irbesartanom manj izrazito.
These limited data indicate no increase in the rate of birth defects compared to rates observed in population-based birth defect surveillance systems.
Ti omejeni podatki ne kažejo večjega deleža prirojenih hib kot je delež, ugotovljen s sistemi populacijskega nadzora prirojenih hib.
These local reactions are short-lived and typically resolve within 2 days.
Tovrstne lokalne reakcije so kratkotrajne in praviloma izginejo v dveh dneh.
These local reactions are transient and typically resolve within 2 days.
Lokalne reakcije so prehodne in običajno minejo v 2 dneh.
These local reactions are transient, and typically resolve within 2 days.
Lokalne reakcije so prehodne in običajno minejo v 2 dneh.
These lymphocytes improve the patient’s ability to fight infection, and so overcome the symptoms of the condition related to the immune system.
Ti limfociti izboljšajo bolnikovo zmožnost bojevanja proti okužbam in tako premagajo simptome bolezenskih stanj, ki so povezana z imunskim sistemom.
These make the vaccine work quicker, better and last for longer.
Ti sestavini dosežeta, da cepivo deluje hitreje, bolje in daljši čas.
These manifestations may be attributable to a pseudoporphyria state (temporary medicinal product-induced cutaneous porphyria).
Te pojave lahko pripišemo stanju psevdoporfirije (trenutna kožna porfirija, ki nastane zaradi zravila).
These may affect 1 to 10 in 100 people:
Ti se lahko pojavijo pri največ 10 od 100 bolnikov:
These may affect 1 to 9 users in 1,000 Affecting the eye abnormal sensation in the eye, itching of the eyelids, swelling of eyelids, tired eyes, darkening of eyelashes.
Pojavijo se lahko pri 1-9 bolnikih od 1000 bolnikov Učinki na oko neobičajen občutek v očesu, srbeče veke, otekanje vek, utrujene oči, temnenje trepalnic.
These may affect 1 to 9 users in 1,000 Affecting the eye iris inflammation, swollen conjunctiva (see-through layer of the eye), painful eyelids, tired eyes, in- growing eyelashes, darker iris colour, eyes appear sunken, eyelid has moved away from the surface of the eye.
Pojavijo se lahko pri 1-9 bolnikih od 1000 bolnikov Učinki na oko vnetje šarenice, otekla očesna veznica (prozorna plast očesa), boleče veke, utrujene oči, vraščene trepalnice, temnejša barva šarenice, oči so videti udrte, odstop veke od površine očesa.
These may affect 1 to 9 users in 100 Affecting the eye
Ti učinki se lahko pojavijo pri 1 do 9 od 100 bolnikov.
These may affect 1 to 9 users in 100 Affecting the eye burning, itching, stinging, sensitivity to light, eye pain, sticky eyes, dry eyes, a feeling of something in the eye, small breaks in the surface of the eye with or without inflammation, difficulty in seeing clearly, redness and itching of the eyelids, darkening of the eyelids, darker skin colour around the eyes, longer eyelashes, eye irritation, watery eyes, swollen eyelids, reduced vision.
Pojavijo se lahko pri 1-9 bolnikih od 100 bolnikov Učinki na oko pekoč občutek, srbenje, skelenje, občutljivost na svetlobo, boleče oko, lepljive oči, suhe oči, občutek tujka v očesu, majhne razpoke na očesni površini z ali brez vnetja, zamegljen vid, pordele in srbeče veke, temnejša koža vek, temnejša barva kože okoli oči, daljše trepalnice, draženje očesa, solzenje, otekle veke, oslabljen vid.
These may affect 1 to 9 users in 100 Affecting the eye small breaks in the surface of the eye with inflammation, eye irritation, irritation of the conjunctiva (see-through layer of the eye), itchy eyes, eye pain, a feeling of something in the eye, dry eyes, watery eyes, redness of the eyelids, sensitivity to light, longer eyelashes.
Pojavijo se lahko pri 1-9 bolnikih od 100 bolnikov Učinki na oko majhne razpoke na površini očesa z vnetjem, draženje očesa, draženje očesne veznice (prozorne plasti očesa), srbenje očesa, boleče oko, občutek tujka v očesu, suho oko, solzenje očesa, rdeče veke, občutljivost na svetlobo, daljše trepalnice.
These may affect more than 1 in 10 people
Pojavijo se pri več kot 1 od 10 bolnikov
These may affect more than 1 in 10 people taking alli
Lahko prizadenejo več kakor 1 od 10 ljudi, ki jemljejo zdravilo alli.
These may affect more than 1 in 10 people using Abseamed.
Pojavijo se lahko pri več kot 1 od 10 bolnikov, ki uporabljajo zdravilo Abseamed
These may affect more than 1 in 10 people using Binocrit.
Pojavijo se lahko pri več kot 1 od 10 bolnikov, ki uporabljajo zdravilo Binocrit
These may affect more than 1 in 10 people using Epoetin alfa HEXAL.
Pojavijo se lahko pri več kot 1 od 10 bolnikov, ki uporabljajo zdravilo Epoetin alfa HEXAL
These may affect more than 1 in 10 people using Retacrit.
Ti se lahko pojavijo pri več kot 1 od 10 bolnikov, ki uporabljajo zdravilo Retacrit.
These may affect more than 1 in 10 people using Silapo.
Ti se lahko pojavijo pri več kot 1 od 10 bolnikov, ki uporabljajo zdravilo Silapo.
These may affect more than 1 in 10 people.
Ti neželeni učinki se lahko pojavijo pri več kot 1 od 10 bolnikov.
These may affect more than 1 in 10 people:
Neželeni učinki, ki se lahko pojavijo pri več kot 1 od 10 bolnikov:
These may affect more than 1 in 10 people:
Pojavijo se lahko pri več kot 1 od 10 oseb:
These may affect more than 1 in 10 people:
Ti neželeni učinki se lahko pojavijo pri več kot 1 od 10 bolnikov: